サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1713186

神経バイオマーカーの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Neurological Biomarkers Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 170 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
神経バイオマーカーの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月23日
発行: Persistence Market Research
ページ情報: 英文 170 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の神経バイオマーカーの市場規模は、2025年に95億米ドルになるとみられ、2025年～2032年の予測期間に10.4%のCAGRで拡大し、2032年には191億米ドルに達すると予測されています。

神経バイオマーカーは、アルツハイマー病、パーキンソン病、多発性硬化症、外傷性脳損傷など、様々な神経疾患の診断、予後、治療モニタリングに不可欠です。これらのバイオマーカーは、血液、脳脊髄液（CSF）、尿などの体液中に存在し、神経疾患の存在を反映する分子シグネチャーの同定に役立ちます。神経学的バイオマーカー市場は、診断ラボ、ヘルスケアプロバイダー、研究機関、製薬会社を対象としており、遺伝子バイオマーカー、タンパク質バイオマーカー、画像バイオマーカーなど、さまざまなタイプのバイオマーカーを提供しています。市場成長の原動力は、神経疾患の有病率の上昇、バイオマーカー探索の進歩、個別化医療の採用の高まりです。

世界の神経バイオマーカー市場は、アルツハイマー病やパーキンソン病などの神経疾患の罹患率の上昇、世界人口の高齢化に伴う罹患率の上昇など、いくつかの重要な要因によって推進されています。非侵襲的な診断検査に対する需要の高まりと、神経疾患の早期発見能力は、市場拡大のさらなる原動力となっています。分子生物学、ゲノミクス、プロテオミクスの進歩は、診断精度と治療成果を高める新規バイオマーカーの同定につながっています。さらに、個別化医療の採用の増加や、薬剤の有効性をモニタリングするための臨床試験におけるバイオマーカーの統合も、市場の成長に寄与しています。

有望な成長見通しにもかかわらず、神経学的バイオマーカー市場は、バイオマーカー開発と検査に関連する高コストに関連する課題に直面しています。規制上のハードルやバイオマーカー検査の標準化の欠如も大きな課題となっています。さらに、神経疾患の複雑な性質や、特に早期疾患の場合、患者から正確なバイオマーカーデータを得ることの難しさが、市場浸透をさらに複雑にしています。また、特に新興市場では、バイオマーカーに基づく検査に対する償還の問題が障壁となり、普及が制限されています。

神経学的バイオマーカー市場は、精密医療、人工知能（AI）の進歩、医薬品開発におけるバイオマーカーの役割の増大によって大きな成長機会がもたらされます。病気の発症予測、病気の進行のモニタリング、治療効果の評価にバイオマーカーが応用されることで、市場関係者に新たな道が開かれつつあります。さらに、早期診断のための非侵襲的で費用対効果の高いバイオマーカーの開発機会が拡大しており、こうした診断ツールの恩恵を受ける患者集団が大幅に拡大する可能性があります。戦略的パートナーシップ、研究投資、より効率的なバイオマーカー検査プラットフォームの開発は、このダイナミックな市場で新たなチャンスを活かすために極めて重要です。

当レポートでは、世界の神経バイオマーカー市場について調査し、バイオマーカー別、サンプル別、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値のある洞察

第4章 世界の神経バイオマーカー市場の見通し

  • 主なハイライト
  • 市場規模の分析と予測
    • 過去の市場規模（10億米ドル）分析、2019年～2024年
    • 現在の市場規模（10億米ドル）分析と予測、2025年～2032年
  • 世界の神経バイオマーカー市場の見通し：バイオマーカー別
    • イントロダクション/主な調査結果
    • 過去の市場規模（10億米ドル）分析、バイオマーカー別、2019年～2024年
    • 現在の市場規模（10億米ドル）分析と予測、バイオマーカー別、2025年～2032年
      • プロテオームバイオマーカー
      • ゲノムバイオマーカー
      • 神経画像バイオマーカー
      • メタボロミクスバイオマーカー
    • 市場の魅力分析：バイオマーカー別
  • 世界の神経バイオマーカー市場の見通し：サンプル別
    • イントロダクション/主な調査結果
    • 過去の市場規模（10億米ドル）分析、サンプル別、2019年～2024年
    • 現在の市場規模（10億米ドル）分析と予測、サンプル別、2025年～2032年
      • 血液
      • 血小板
      • 脳脊髄液
      • その他
    • 市場の魅力分析：サンプル別
  • 世界の神経バイオマーカー市場の見通し：適応症別
    • イントロダクション/主な調査結果
    • 過去の市場規模（10億米ドル）分析、適応症別、2019年～2024年
    • 現在の市場規模（10億米ドル）分析と予測、適応症別、2025年～2032年
      • アルツハイマー病（AD）
      • 多発性硬化症（MS）
      • パーキンソン病（PD）
      • 自閉症スペクトラム障害（ASD）
      • その他
    • 市場の魅力分析：適応症別
  • 世界の神経バイオマーカー市場の見通し：エンドユーザー別
    • イントロダクション/主な調査結果
    • 過去の市場規模（10億米ドル）分析、エンドユーザー別、2019年～2024年
    • 現在の市場規模（10億米ドル）分析と予測、エンドユーザー別、2025年～2032年
      • 病院検査室
      • 診断センター
      • 学術研究機関
      • バイオ医薬品企業
      • プロテオーム研究室
      • その他
    • 市場の魅力分析：エンドユーザー別

第5章 世界の神経バイオマーカー市場の見通し：地域別

  • 主なハイライト
  • 過去の市場規模（10億米ドル）分析、地域別、2019年～2024年
  • 現在の市場規模（10億米ドル）分析と予測、地域別、2025年～2032年
    • 北米
    • 欧州
    • 東アジア
    • 南アジアとオセアニア
    • ラテンアメリカ
    • 中東・アフリカ
    • 市場の魅力分析：地域別

第6章 北米の神経バイオマーカー市場の見通し

第7章 欧州の神経バイオマーカー市場の見通し

第8章 東アジアの神経バイオマーカー市場の見通し

第9章 南アジアおよびオセアニアの神経バイオマーカー市場の見通し

第10章 ラテンアメリカの神経バイオマーカー市場の見通し

第11章 中東・アフリカの神経バイオマーカー市場の見通し

第12章 競合情勢

  • 市場シェア分析、2025年
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Quanterix
    • Amoneta Diagnostics
    • Bio-Rad Laboratories, Inc
    • Eli Lilly and Company
    • IXICO plc
    • Biognosys
    • Revvity
    • Beckman Coulter, Inc.
    • PreOmics GmbH
    • ADx NeuroSciences NV（A Fujirebio Company）
    • Fujirebio
    • Brainomix
    • Merck KGaA
    • Bio-Techne
    • Assay Genie
    • SomaLogic Operating Co., Inc.
    • Siemens Healthineers
    • Abbott Laboratories
    • Roche Diagnostics
    • GE HealthCare
    • Imaging Endpoints

第13章 付録

目次
Product Code: PMRREP16303

Persistence Market Research has recently released a comprehensive report on the worldwide market for neurological biomarkers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global neurological biomarkers market from 2025 to 2032.

Key Insights:

  • Neurological Biomarkers Market Size (2025E): USD 9.5 Billion
  • Projected Market Value (2032F): USD 19.1 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 10.4%

Neurological Biomarkers Market - Report Scope:

Neurological biomarkers are vital for the diagnosis, prognosis, and treatment monitoring of various neurological diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injuries. These biomarkers can be found in biological fluids such as blood, cerebrospinal fluid (CSF), and urine, and they help in identifying molecular signatures that reflect the presence of neurological conditions. The neurological biomarkers market caters to diagnostic labs, healthcare providers, research institutions, and pharmaceutical companies, offering a range of biomarker types, including genetic biomarkers, protein biomarkers, and imaging biomarkers. Market growth is driven by increasing prevalence of neurological disorders, advancements in biomarker discovery, and the rising adoption of personalized medicine.

Market Growth Drivers:

The global neurological biomarkers market is propelled by several key factors, including the growing incidence of neurological diseases such as Alzheimer's and Parkinson's disease, which are becoming more prevalent with an aging global population. The increasing demand for non-invasive diagnostic tests and the ability to detect neurological disorders at earlier stages further drive market expansion. Advances in molecular biology, genomics, and proteomics have led to the identification of novel biomarkers that enhance diagnostic accuracy and treatment outcomes. Moreover, the increasing adoption of personalized medicine and the integration of biomarkers in clinical trials to monitor drug efficacy also contribute to the market's growth.

Market Restraints:

Despite promising growth prospects, the neurological biomarkers market faces challenges related to the high costs associated with biomarker development and testing. Regulatory hurdles and the lack of standardization in biomarker testing also pose significant challenges. Additionally, the complex nature of neurological disorders and the difficulty in obtaining accurate biomarker data from patients, particularly in the case of early-stage diseases, further complicate market penetration. The market also faces barriers in terms of reimbursement issues for biomarker-based tests, especially in emerging markets, limiting widespread adoption.

Market Opportunities:

The neurological biomarkers market presents significant growth opportunities driven by advancements in precision medicine, artificial intelligence (AI), and the increasing role of biomarkers in drug development. The application of biomarkers in predicting disease onset, monitoring disease progression, and assessing treatment responses is opening new avenues for market players. Additionally, there is a growing opportunity for the development of non-invasive and cost-effective biomarkers for early diagnosis, which could significantly expand the patient population benefiting from these diagnostic tools. Strategic partnerships, research investments, and the development of more efficient biomarker testing platforms are crucial for capitalizing on emerging opportunities in this dynamic market.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the neurological biomarkers market globally?
  • Which types of biomarkers are most commonly used in the diagnosis and monitoring of neurological diseases?
  • How are technological advancements reshaping the competitive landscape of the neurological biomarkers market?
  • Who are the key players contributing to the neurological biomarkers market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global neurological biomarkers market?

Competitive Intelligence and Business Strategy:

Leading players in the global neurological biomarkers market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to discover novel biomarkers and develop new diagnostic platforms. Collaborations with academic institutions, healthcare providers, and pharmaceutical companies help accelerate biomarker validation and commercialization. Moreover, the development of AI-driven platforms to enhance the precision of biomarker analysis and improve diagnostic workflows is also gaining traction in the market.

Key Companies Profiled:

  • Quanterix
  • Amoneta Diagnostics
  • Bio-Rad Laboratories, Inc
  • Eli Lilly and Company
  • IXICO plc
  • Biognosys
  • Revvity
  • Beckman Coulter, Inc.
  • PreOmics GmbH
  • ADx NeuroSciences NV (A Fujirebio Company)
  • Fujirebio
  • Brainomix
  • Merck KGaA
  • Bio-Techne
  • Assay Genie
  • SomaLogic Operating Co., Inc.
  • Siemens Healthineers
  • Abbott Laboratories
  • Roche Diagnostics
  • GE HealthCare
  • Imaging Endpoints

Market Segmentation:

Neurological Biomarkers Market Research Segmentation: The neurological biomarkers market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various neurological conditions.

By Biomarkers Type

  • Proteomic Biomarkers
  • Genomic Biomarkers
  • Neuroimaging Biomarkers
  • Metabolomics Biomarkers

By Sample

  • Blood
  • Plasma
  • Cerebrospinal Fluid
  • Others

By Indication

  • Alzheimer's disease (AD)
  • Multiple sclerosis (MS)
  • Parkinson's disease (PD)
  • Autism spectrum disorder (ASD)
  • Others

By End-user

  • Hospital Labs
  • Diagnostic Centers
  • Academic & Research Institutes
  • Biopharma Companies
  • Proteomic Laboratory
  • Others

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Neurological Biomarkers Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Neurological Biomarkers Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Neurological Biomarkers Market Outlook: Biomarkers
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Biomarker, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
      • 4.3.3.1. Proteomic Biomarkers
      • 4.3.3.2. Genomic Biomarkers
      • 4.3.3.3. Neuroimaging Biomarkers
      • 4.3.3.4. Metabolomics Biomarkers
    • 4.3.4. Market Attractiveness Analysis: Biomarkers
  • 4.4. Global Neurological Biomarkers Market Outlook: Sample
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Sample, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
      • 4.4.3.1. Blood
      • 4.4.3.2. Plasma
      • 4.4.3.3. Cerebrospinal Fluid
      • 4.4.3.4. Others
    • 4.4.4. Market Attractiveness Analysis: Sample
  • 4.5. Global Neurological Biomarkers Market Outlook: Indication
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
      • 4.5.3.1. Alzheimer's Disease (AD)
      • 4.5.3.2. Multiple Sclerosis (MS)
      • 4.5.3.3. Parkinson's Disease (PD)
      • 4.5.3.4. Autism Spectrum Disorder (ASD)
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: Indication
  • 4.6. Global Neurological Biomarkers Market Outlook: End-user
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By End-user, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
      • 4.6.3.1. Hospital Labs
      • 4.6.3.2. Diagnostic Centers
      • 4.6.3.3. Academic & Research Institutes
      • 4.6.3.4. Biopharma Companies
      • 4.6.3.5. Proteomic Laboratory
      • 4.6.3.6. Others
    • 4.6.4. Market Attractiveness Analysis: End-user

5. Global Neurological Biomarkers Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia & Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
    • 5.3.7. Market Attractiveness Analysis: Region

6. North America Neurological Biomarkers Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Biomarker
    • 6.2.3. By Sample
    • 6.2.4. By Indication
    • 6.2.5. By End-user
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 6.4.1. Proteomic Biomarkers
    • 6.4.2. Genomic Biomarkers
    • 6.4.3. Neuroimaging Biomarkers
    • 6.4.4. Metabolomics Biomarkers
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 6.5.1. Blood
    • 6.5.2. Plasma
    • 6.5.3. Cerebrospinal Fluid
    • 6.5.4. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 6.6.1. Alzheimer's Disease (AD)
    • 6.6.2. Multiple Sclerosis (MS)
    • 6.6.3. Parkinson's Disease (PD)
    • 6.6.4. Autism Spectrum Disorder (ASD)
    • 6.6.5. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 6.7.1. Hospital Labs
    • 6.7.2. Diagnostic Centers
    • 6.7.3. Academic & Research Institutes
    • 6.7.4. Biopharma Companies
    • 6.7.5. Proteomic Laboratory
    • 6.7.6. Others
  • 6.8. Market Attractiveness Analysis

7. Europe Neurological Biomarkers Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Biomarker
    • 7.2.3. By Sample
    • 7.2.4. By Indication
    • 7.2.5. By End-user
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 7.4.1. Proteomic Biomarkers
    • 7.4.2. Genomic Biomarkers
    • 7.4.3. Neuroimaging Biomarkers
    • 7.4.4. Metabolomics Biomarkers
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 7.5.1. Blood
    • 7.5.2. Plasma
    • 7.5.3. Cerebrospinal Fluid
    • 7.5.4. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 7.6.1. Alzheimer's Disease (AD)
    • 7.6.2. Multiple Sclerosis (MS)
    • 7.6.3. Parkinson's Disease (PD)
    • 7.6.4. Autism Spectrum Disorder (ASD)
    • 7.6.5. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 7.7.1. Hospital Labs
    • 7.7.2. Diagnostic Centers
    • 7.7.3. Academic & Research Institutes
    • 7.7.4. Biopharma Companies
    • 7.7.5. Proteomic Laboratory
    • 7.7.6. Others
  • 7.8. Market Attractiveness Analysis

8. East Asia Neurological Biomarkers Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Biomarker
    • 8.2.3. By Sample
    • 8.2.4. By Indication
    • 8.2.5. By End-user
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 8.4.1. Proteomic Biomarkers
    • 8.4.2. Genomic Biomarkers
    • 8.4.3. Neuroimaging Biomarkers
    • 8.4.4. Metabolomics Biomarkers
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 8.5.1. Blood
    • 8.5.2. Plasma
    • 8.5.3. Cerebrospinal Fluid
    • 8.5.4. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 8.6.1. Alzheimer's Disease (AD)
    • 8.6.2. Multiple Sclerosis (MS)
    • 8.6.3. Parkinson's Disease (PD)
    • 8.6.4. Autism Spectrum Disorder (ASD)
    • 8.6.5. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 8.7.1. Hospital Labs
    • 8.7.2. Diagnostic Centers
    • 8.7.3. Academic & Research Institutes
    • 8.7.4. Biopharma Companies
    • 8.7.5. Proteomic Laboratory
    • 8.7.6. Others
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Neurological Biomarkers Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Biomarker
    • 9.2.3. By Sample
    • 9.2.4. By Indication
    • 9.2.5. By End-user
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 9.4.1. Proteomic Biomarkers
    • 9.4.2. Genomic Biomarkers
    • 9.4.3. Neuroimaging Biomarkers
    • 9.4.4. Metabolomics Biomarkers
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 9.5.1. Blood
    • 9.5.2. Plasma
    • 9.5.3. Cerebrospinal Fluid
    • 9.5.4. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 9.6.1. Alzheimer's Disease (AD)
    • 9.6.2. Multiple Sclerosis (MS)
    • 9.6.3. Parkinson's Disease (PD)
    • 9.6.4. Autism Spectrum Disorder (ASD)
    • 9.6.5. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 9.7.1. Hospital Labs
    • 9.7.2. Diagnostic Centers
    • 9.7.3. Academic & Research Institutes
    • 9.7.4. Biopharma Companies
    • 9.7.5. Proteomic Laboratory
    • 9.7.6. Others
  • 9.8. Market Attractiveness Analysis

10. Latin America Neurological Biomarkers Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Biomarker
    • 10.2.3. By Sample
    • 10.2.4. By Indication
    • 10.2.5. By End-user
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 10.4.1. Proteomic Biomarkers
    • 10.4.2. Genomic Biomarkers
    • 10.4.3. Neuroimaging Biomarkers
    • 10.4.4. Metabolomics Biomarkers
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 10.5.1. Blood
    • 10.5.2. Plasma
    • 10.5.3. Cerebrospinal Fluid
    • 10.5.4. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 10.6.1. Alzheimer's Disease (AD)
    • 10.6.2. Multiple Sclerosis (MS)
    • 10.6.3. Parkinson's Disease (PD)
    • 10.6.4. Autism Spectrum Disorder (ASD)
    • 10.6.5. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 10.7.1. Hospital Labs
    • 10.7.2. Diagnostic Centers
    • 10.7.3. Academic & Research Institutes
    • 10.7.4. Biopharma Companies
    • 10.7.5. Proteomic Laboratory
    • 10.7.6. Others
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Neurological Biomarkers Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Biomarker
    • 11.2.3. By Sample
    • 11.2.4. By Indication
    • 11.2.5. By End-user
  • 11.3. Current Market Size (US$ Bn) and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Biomarker, 2025-2032
    • 11.4.1. Proteomic Biomarkers
    • 11.4.2. Genomic Biomarkers
    • 11.4.3. Neuroimaging Biomarkers
    • 11.4.4. Metabolomics Biomarkers
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Sample, 2025-2032
    • 11.5.1. Blood
    • 11.5.2. Plasma
    • 11.5.3. Cerebrospinal Fluid
    • 11.5.4. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
    • 11.6.1. Alzheimer's Disease (AD)
    • 11.6.2. Multiple Sclerosis (MS)
    • 11.6.3. Parkinson's Disease (PD)
    • 11.6.4. Autism Spectrum Disorder (ASD)
    • 11.6.5. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2025-2032
    • 11.7.1. Hospital Labs
    • 11.7.2. Diagnostic Centers
    • 11.7.3. Academic & Research Institutes
    • 11.7.4. Biopharma Companies
    • 11.7.5. Proteomic Laboratory
    • 11.7.6. Others
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Quanterix
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Amoneta Diagnostics
    • 12.3.3. Bio-Rad Laboratories, Inc
    • 12.3.4. Eli Lilly and Company
    • 12.3.5. IXICO plc
    • 12.3.6. Biognosys
    • 12.3.7. Revvity
    • 12.3.8. Beckman Coulter, Inc.
    • 12.3.9. PreOmics GmbH
    • 12.3.10. ADx NeuroSciences NV (A Fujirebio Company)
    • 12.3.11. Fujirebio
    • 12.3.12. Brainomix
    • 12.3.13. Merck KGaA
    • 12.3.14. Bio-Techne
    • 12.3.15. Assay Genie
    • 12.3.16. SomaLogic Operating Co., Inc.
    • 12.3.17. Siemens Healthineers
    • 12.3.18. Abbott Laboratories
    • 12.3.19. Roche Diagnostics
    • 12.3.20. GE HealthCare
    • 12.3.21. Imaging Endpoints

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations